Suspected oncologic adverse reactions associated with interleukin ‐23 inhibitors in EudraVigilance: Comparative study and gender distribution

This study investigated the occurrence of malignancies as suspected adverse reactions (SARs) potentially associated with IL-23 inhibitors by analyzing real-world data from the European EudraVigilance database. Although indicatory, these real-world data seem to confirm the potential association between the IL-23 inhibitors risankizumab and tildrakizumab, and the occurrence of SARs linked to cancer in patients with psoriasis and, according to a gender perspective, they show that this relationship is asymmetrically distributed between women and men, with a clear prevalence of oncologic SARs in men.
Source: Pharmacology Research and Perspectives - Category: Drugs & Pharmacology Authors: Tags: SHORT REPORT Source Type: research